Table 1.
Inhibitory effect of tested compounds against the proliferation of murine leukaemia (L1210), human T-lymphocyte (CEM) and human cervix carcinoma cells (HeLa).
| Compound | B | IC50a (μM) |
||
|---|---|---|---|---|
| CEM | L1210 | HeLa | ||
| 20e | N3-Benzoylquinazoline-2,4-dione | ≥72 | >200 | ≥89 |
| 20f | 6-Azauracil | >200 | >200 | >200 |
| 20g | 8-Chlorotheophylline | >200 | >200 | >200 |
| 20h | Theobromine | >200 | >200 | ≥149 |
| 20i | Theophylline | >200 | >200 | >200 |
| 20j | 5,6-Dimethylbenzimidazole | 97 ± 35 | >200 | 42 ± 16 |
| 20k | 3-Acetylindole | 2.78 ± 1.4 | 72 ± 19 | 11 ± 7.6 |
| 20l | 2-Pyridon | >200 | >200 | >200 |
| 21f | 6-Azauracil | >200 | >200 | >200 |
| 21g | 8-Chlorotheophylline | >200 | >200 | 200 |
| 21h | Theobromine | >200 | >200 | 159 ± 59 |
| 21i | Theophylline | >200 | >200 | >200 |
| 21j | 5,6-Dimethylbenzimidazole | 23.4 ± 7.9 | ≥200 | >200 |
| 21k | 3-Acetylindole | 11.4 ± 2.2 | 197 ± 4.2 | 18 ± 3.5 |
| 21l | 2-Pyridon | >200 | >200 | >200 |
| 22e | N3-Benzoylquinazoline-2,4-dione | 44 ± 42 | >200 | 129 ± 78 |
| 22f | 6-Azauracil | >200 | >200 | >200 |
| 22g | 8-Chlorotheophylline | >200 | >200 | >200 |
| 22h | Theobromine | >200 | >200 | >200 |
| 22i | Theophylline | >200 | >200 | >200 |
| 22j | 5,6-Dimethylbenzimidazole | 14 ± 8.3 | 189 ± 16 | 101 ± 23 |
| 22k | 3-Acetylindole | 4.54 ± 1.24 | 164 ± 52 | 19 ± 13 |
| 22l | 2-Pyridon | >200 | >200 | >200 |
| 22m | N3-Benzoyluracil | >200 | >200 | >200 |
| 23a | Adenine | >200 | >200 | >200 |
| 23b | Thymine | >200 | >200 | >200 |
| 23c | Uracil | >200 | >200 | >200 |
| 23d | N4-Acetylcytosine | >200 | >200 | >200 |
| 23f | 6-Azauracil | >200 | >200 | >200 |
| 23g | 8-Chlorotheophylline | >200 | >200 | >200 |
| 23h | Theobromine | >200 | >200 | >200 |
| 23i | Theophylline | >200 | >200 | >200 |
| 23j | 5,6-Dimethylbenzimidazole | 24.7 ± 8.1 | >200 | 172 ± 40 |
| 23k | 3-Acetylindole | 12 ± 3.5 | 200 | >200 |
| 23l | 2-Pyridon | >200 | >200 | >200 |
| 24e | N3-Benzoylquinazoline-2,4-dione | ≥77 | >200 | >200 |
| 24f | 6-Azauracil | >200 | >200 | >200 |
| 24g | 8-Chlorotheophylline | >200 | >200 | >200 |
| 24h | Theobromine | >200 | >200 | >200 |
| 24i | Theophylline | >200 | >200 | >200 |
| 24j | 5,6-Dimethylbenzimidazole | >200 | >200 | >200 |
| 24k | 3-Acetylindole | 21 ± 0.14 | >200 | >200 |
| 24l | 2-Pyridon | >200 | >200 | >200 |
| 25e | N3-Benzoylquinazoline-2,4-dione | 72 ± 45 | >200 | >200 |
| 25f | 6-Azauracil | >200 | >200 | >200 |
| 25g | 8-Chlorotheophylline | >200 | >200 | >200 |
| 25h | Theobromine | >200 | >200 | >200 |
| 25i | Theophylline | >200 | >200 | >200 |
| 25j | 5,6-Dimethylbenzimidazole | 78 ± 26 | >200 | ≥150 |
| 25k | 3-Acetylindole | 43 ± 3.5 | >200 | 97 ± 80 |
| 25l | 2-Pyridon | >200 | >200 | >200 |
| 26b | Thymine | >200 | >200 | >200 |
| 26c | Uracil | >200 | >200 | >200 |
| 26d | N4-Acetylcytosine | >200 | >200 | >200 |
| 26e | N3-Benzoylquinazoline-2,4-dione | 70 ± 18 | >200 | >200 |
| 26f | 6-Azauracil | >200 | >200 | >200 |
| 26g | 8-Chlorotheophylline | >200 | >200 | >200 |
| 26h | Theobromine | >200 | >200 | >200 |
| 26i | Theophylline | >200 | >200 | >200 |
| 26j | 5,6-Dimethylbenzimidazole | 163 ± 53 | >200 | >200 |
| 26k | 3-Acetylindole | 100 ± 2.8 | 124 ± 62 | >200 |
| 26l | 2-Pyridon | >200 | >200 | >200 |
| 31e | N3-Benzoylquinazoline-2,4-dione | >200 | >200 | >200 |
| 31g | 8-Chlorotheophylline | >200 | >200 | >200 |
| 31j | 5,6-Dimethylbenzimidazole | >200 | >200 | >200 |
| 31m | N3-Benzoyluracil | >200 | >200 | >200 |
| 32a | Adenine | >200 | >200 | >200 |
| 32b | Thymine | >200 | >200 | >200 |
| 32c | Uracil | >200 | >200 | >200 |
| 33i | Theophylline | >200 | >200 | >200 |
a
50% Inhibitory concentration or compound concentration required to inhibit tumour cell proliferation by 50%.